US Gangrene Market Research Report By Type (Dry Gangrene, Wet Gangrene, Gas Gangrene) - Forecast to 2035

US Gangrene Market Overview

As per MRFR analysis, the US Gangrene Market Size was estimated at 318.5 (USD Million) in 2023. The US Gangrene Market Industry is expected to grow from 350(USD Million) in 2024 to 770 (USD Million) by 2035. The US Gangrene Market CAGR (growth rate) is expected to be around 7.431% during the forecast period (2025 - 2035).

Key US Gangrene Market Trends Highlighted

The US Gangrene Market is currently witnessing several significant trends shaped by advancements in medical technology, changing patient demographics, and an increased focus on infection control. One key market driver is the rising incidence of chronic conditions, such as diabetes, which is leading to a higher occurrence of gangrene cases among patients. With an aging population and increasing prevalence rates of obesity and diabetes in the US, healthcare providers are under pressure to effectively manage and treat such cases.

This growing patient pool, coupled with the rising awareness of gangrene, drives the demand for effective medical treatments and surgical procedures. Opportunities are emerging in telemedicine and home healthcare services, which provide potential market players with avenues to reach patients more effectively. As the healthcare system evolves towards more accessible and patient-centric approaches, telehealth solutions can facilitate remote monitoring and early intervention in individuals at risk of developing gangrene.

Moreover, innovations in wound care treatments and regenerative medicine present new prospects for addressing complications arising from gangrene, an area where research and development investments could yield significant benefits. Recent trends also reveal a shift towards advanced therapies and personalized treatment plans, supported by growing health awareness campaigns and educational initiatives highlighting the risks of untreated wounds and infections.

This trend is further supported by government efforts to improve healthcare access and quality, emphasizing the need for proactive disease management. Furthermore, collaboration between governmental health agencies and private sector organizations is on the rise, aiming to bolster research initiatives and create a better understanding of gangrene through data sharing and community outreach. Overall, these trends indicate a promising dynamic in the US Gangrene Market as it adapts to meet the evolving needs of patients and healthcare providers.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Gangrene Market Drivers

Increasing Incidence of Diabetes and Obesity

The rising prevalence of diabetes and obesity in the United States is a significant driver for the US Gangrene Market Industry. According to the Centers for Disease Control and Prevention (CDC), as of 2020, over 34 million Americans, or approximately 10.5% of the population, have diabetes. This condition often leads to poor blood circulation and increases the risk of gangrene, particularly in diabetic foot ulcers.

Furthermore, the CDC reported that approximately 42.4% of adults in the US were classified as obese in 2017-2018, which significantly heightens the risk factors associated with gangrene. Major healthcare organizations like the American Diabetes Association (ADA) actively work towards increasing awareness and management of diabetes, which indirectly influences the growth of the gangrene market, as managing these conditions remains a priority to mitigate complications such as gangrene.

Advancements in Surgical and Wound Care Technologies

Recent advancements in surgical techniques and wound care products bolster the US Gangrene Market Industry by improving patient outcomes and recovery times. Innovations such as skin grafting, negative pressure wound therapy, and advanced antimicrobial dressings are becoming standard practices in treating gangrene-related conditions. A report by the American College of Surgeons indicates that the adoption of minimally invasive surgical techniques has increased by nearly 20% in the last five years.

These advancements not only enhance treatment efficacy but also lead to a reduction in hospital stay duration, thereby promoting market growth as facilities invest in these technologies to improve patient care.

Increase in Aged Population Prone to Ischemic Diseases

The aging population in the United States significantly contributes to the growth of the US Gangrene Market Industry. According to the Administration for Community Living, by 2030, one in five Americans will be over the age of 65, a demographic known to be more vulnerable to ischemic diseases, which can lead to gangrene. As older adults often present with multiple comorbidities including vascular diseases and diabetes, they require more comprehensive care.

The aging trend implies a higher demand for medical interventions, contributing to increased healthcare spending and development of treatments focused on gangrene management.

US Gangrene Market Segment Insights

Gangrene Market Type Insights

The US Gangrene Market is characterized by a varied segmentation based on Type, which includes significant categories such as Dry Gangrene, Wet Gangrene, and Gas Gangrene. Each of these types presents unique challenges and treatment requirements, indicating the complexity of managing gangrene cases. Dry Gangrene occurs when blood flow to a particular area is obstructed, leading to tissue death. This type is often associated with conditions like diabetes or atherosclerosis, making it crucial for early detection and effective management to prevent further complications in patients.

Wet Gangrene, on the other hand, is typically due to bacterial infection that causes rapid tissue decay and can result from untreated wounds or severe burns, presenting urgent public health challenges. Its rapid progression underscores the need for prompt medical intervention, often requiring advanced treatment strategies to mitigate infection spread and tissue loss. Lastly, Gas Gangrene is characterized by the production of gas within tissues due to clostridial bacteria; this type can manifest suddenly and is often life-threatening.

The severity and rapid onset of Gas Gangrene emphasize the importance of immediate medical response and advanced surgical options, highlighting the critical nature of awareness and education in primary care settings. Collectively, these distinct types contribute to the broader understanding of the US Gangrene Market dynamics, shaping treatment paradigms and influencing healthcare resource allocation in the United States.

The complexity and varied nature of these gangrene types present both challenges and opportunities for healthcare professionals, as they adapt to evolving market trends and implement effective treatment pathways. Understanding these types is essential for improving patient outcomes, enhancing the quality of care, and driving advancements in Research and Development within the US healthcare system. These characteristics contribute to the market's growth trajectory, presenting avenues for innovation and improvement in patient care strategies.

 

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

US Gangrene Market Key Players and Competitive Insights

The competitive insights of the US Gangrene Market show a landscape characterized by several prominent players driving innovation and market growth. The competition within this sector is shaped by the increasing prevalence of gangrene and the rising demand for effective treatment options. Various companies are investing in research and development to enhance their portfolios, seeking to introduce new therapies that address different types of gangrene, including wet, dry, and gas gangrene.

The regulatory environment in the US further influences market dynamics as firms strive to comply with strict standards while developing products that are both effective and safe for patients. The competitive advantage often hinges upon the ability to offer innovative therapies, coupled with strong marketing strategies and strategic collaborations. Merck and Co stands out in the US Gangrene Market due to its robust pipeline and established presence in the pharmaceutical landscape.

The company is recognized for its commitment to developing cutting-edge therapeutic solutions, which allows it to cater effectively to the needs of healthcare professionals and patients affected by gangrene. Leveraging its extensive research capabilities and a strong distribution network, Merck and Co has positioned itself to capitalize on the growing demand for advanced treatment options. The company's strengths lie in its continuous investment in clinical trials and research initiatives aimed at improving patient outcomes, ultimately enhancing its competitive position in the market.

Bristol Myers Squibb also plays a significant role in the US Gangrene Market, focusing on delivering innovative products and services that effectively address the challenges associated with gangrene treatment. The company boasts a diversified portfolio with key products that include therapies specifically developed for infection management, which is critical in gangrene cases. Bristol Myers Squibb has made notable strides in expanding its market presence through strategic mergers and acquisitions, facilitating access to advanced research capabilities and therapeutic innovations. The company’s strengths are highlighted by its agile response to market needs and its ability to leverage collaborations to enhance its offerings, thus solidifying its position in the competitive landscape of the US Gangrene Market.

Key Companies in the US Gangrene Market Include

• Merck and Co


• Bristol Myers Squibb


• AstraZeneca


• Novartis


• Gilead Sciences


• Eli Lilly and Company


• Regeneron Pharmaceuticals


• Pfizer


• Amgen


• AbbVie


• Biogen


• Roche


• Sanofi


• Johnson and Johnson

US Gangrene Market Industry Developments

Recent developments in the US Gangrene Market have highlighted significant advancements in treatment options and research initiatives. Companies such as Merck and Co., Bristol Myers Squibb, and Gilead Sciences have been focusing on new therapeutic compounds targeting gangrene-related conditions. In terms of mergers and acquisitions, notable activity includes Novartis acquiring a promising biotechnology firm in September 2023, which is expected to enhance its portfolio in the treatment of chronic wounds associated with gangrene.

Additionally, Pfizer has expanded its research partnerships to explore innovative therapies that reduce gangrene incidence. Market valuation has seen growth due to increasing investments in biotechnology and novel drug development, with Eli Lilly and Company and Amgen reporting substantial quarterly earnings attributed to their advancements in wound care therapies. Over the last few years, there has been a heightened emphasis on antibiotic resistance, with Roche and Sanofi launching collaborative efforts aimed at overcoming resistant infections related to gangrene in April 2022.

These activities have collectively contributed to an evolving landscape in the US Gangrene Market, bolstered by increasing healthcare expenditures and a focus on advanced treatment methodologies.

US Gangrene Market Segmentation Insights

Gangrene Market Type Outlook

• Dry Gangrene


• Wet Gangrene


• Gas Gangrene

Report Scope:

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	318.5(USD Million)
MARKET SIZE 2024	350.0(USD Million)
MARKET SIZE 2035	770.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	7.431% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Merck and Co, Bristol Myers Squibb, AstraZeneca, Novartis, Gilead Sciences, Eli Lilly and Company, Regeneron Pharmaceuticals, Pfizer, Amgen, AbbVie, Biogen, Roche, Sanofi, Johnson and Johnson
SEGMENTS COVERED	Type
KEY MARKET OPPORTUNITIES	Rising prevalence of diabetes, Increasing surgical procedures, Advanced wound care technologies, Growing awareness of gangrene, Government funding for research
KEY MARKET DYNAMICS	rising infection rates, increasing surgical procedures, growing diabetic population, advancements in treatment options, awareness and education initiatives
COUNTRIES COVERED	US